1. Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. The scope of the Study
2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Analytics Tools & Model
2.4. Economic Indicators
2.4.1.Base Year, Base Currency & Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
3. Market Analysis
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyers
3.2.3 Threat of Substitutes
3.2.4 Threat of New Entrants
3.2.5 Industry Rivalry (Competitive Environment)
3.3. PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4. SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.4.5 Y-O-Y Analysis
4. Market Dynamics
4.1. Drivers
4.1.1 Increase in corporate partnerships to accelerate development and commercialise of regenerative medicine.
4.1.2 Increase in global healthcare expenditure.
4.1.3 Rapid growth in ageing population.
4.1.4. Prevalence of chronic diseases and genetic disorders.
4.2. Restraints
4.2.1 Cost of treatment.
4.2.2 Complex regeneration process.
4.2.3. Lack of guidelines.
4.2.4. Ethical concerns with the use of embryonic stem cell for research and development.
4.3. Opportunities
4.3.1. Strong product pipeline.
4.3.2. Great Demand for organ transplantation.
4.4. Challenges
4.4.1 Stringent regulatory policies about stem cell technologies.
5. Global Regenerative Medicine Market – By Product
5.1 Introduction
5.2 Cell-based products
5.2.1 Allogeneic products
5.2.2 Autologous products
5.3 Acellular products
6. Global Regenerative Medicine Market - By Application
6.1 Introduction
6.2 Orthopaedic and musculoskeletal disorders
6.3 Dermatology
6.4 Cardiology
6.5 Central nervous system diseases
6.6 Oncology
6.7 Diabetes
6.8 Bone graft substitutes
6.9 Others
7. Global Regenerative Medicine Market – By Therapy
7.1 Introduction
7.2 Cell therapy
7.3 Immunotherapy
7.4 Tissue therapy
7.5 Gene therapy
7.6 Others
8. Global Regenerative Medicine Market – By Material
8.1 Introduction
8.2 Algae-derived alginate
8.3 Synthetic polymer
8.4 Poly-lactide-coglycolide
8.5 Poly-ethylene glycol
8.6 Hydrogels
8.7 Others
9. Global Regenerative Medicine Market – by Agent type
9.1 Introduction
9.2 Biologics
9.2.1 Autologous fibroblasts
9.2.2 Hematopoietic stem and progenitor cells
9.3 Cell-based medical devices
9.3.1 Allogenic fibroblasts
9.3.2 Cell extraction
9.4 Biopharmaceuticals
9.4.1 Tricalcium phosphate
9.4.2 Osteogenic protein
10. Global Regenerative Medicine Market – By Geography
10.1 North America
10.1.1 Introduction
10.1.2 United States
10.1.3 Canada
10.1.4 Mexico
10.1.5 Others
10.2 Europe
10.2.1 Introduction
10.2.2 France
10.2.3 Germany
10.2.4 Italy
10.2.5 United Kingdom
10.2.6 Spain
10.2.7 Russia
10.2.8 Others
10.3 Asia-pacific
10.3.1 Introduction
10.3.2 China
10.3.3 Japan
10.3.4 India
10.3.5 Australia & New Zealand
10.3.6 Others
10.4 South America
10.4.1 Introduction
10.4.2 Brazil
10.4.3 Argentina
10.4.4 Others
10.5 The Middle East and Africa
10.5.1 Introduction
10.5.2 Saudi Arabia
10.5.3 Israel
10.5.4 UAE
10.5.5 Others
11. Global Regenerative Medicine Market - Company Profiles
11.1 Stryker Corporation
11.2 CONMED Corporation
11.3 Anika Therapeutics Inc.
11.4 Zimmer Holdings Inc.
11.5 Medtronic Inc.
11.6 Vericel corporation
11.7 Baxter International Inc.
11.8 Acelity
11.9 DePuy Synthes Inc.
11.10 StemCells Inc.
11.11 rthrex Inc.
11.12 rganogenesis
11.13 immer biomet holdings
11.14 uvasive
11.15 mith & Nephew PLC
11.16 integra lifesciences corporation
12. Global Regenerative Medicine Market - Competitive Landscape
12.1 Market Share Analysis
12.2 Strategies Adopted by top companies
12.3 Merges, Acquisitions, Collaborations & Agreements
13. Market Insights
13.1 Industry Experts Insights
13.2 Analysts Opinions
13.3 Investment Opportunities
14. Appendix
14.1 List of tables
14.2 List of figures
